2021 Worldwide Chronic Obstructive Pulmonary Disease Industry Report – Featuring Afimmune, Allakos and Astellas Pharma Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic obstructive pulmonary disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic obstructive pulmonary disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease Emerging Drugs Chapters

This segment of the Chronic obstructive pulmonary disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic obstructive pulmonary disease Emerging Drugs

• Itepekimab: Sanofi/ Regeneron
• Ensifentrine: Verona Pharma
• Tezepelumab: Amgen/ AstraZeneca
• BCT-197: Mereo Biopharma

Chronic obstructive pulmonary disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic obstructive pulmonary disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic obstructive pulmonary disease

There are approx. 60+ key companies which are developing the therapies for Chronic obstructive pulmonary disease. The companies which have their Chronic obstructive pulmonary disease drug candidates in the most advanced stage, i.e. Phase III include, Sanofi/ Regeneron.

Phases

This report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic obstructive pulmonary disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic obstructive pulmonary disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic obstructive pulmonary disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic obstructive pulmonary disease drugs.

Chronic obstructive pulmonary disease Report Insights

• Chronic obstructive pulmonary disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic obstructive pulmonary disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic obstructive pulmonary disease drugs?
• How many Chronic obstructive pulmonary disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic obstructive pulmonary disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic obstructive pulmonary disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic obstructive pulmonary disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

• Afimmune
• Allakos
• Amgen/AstraZeneca
• Arrowhead Pharmaceuticals
• Astellas Pharma
• AstraZeneca
• Boehringer-Ingelheim
• Brickell Biotech
• Chiesi Farmaceutici S.p.A.
• CHIESI USA, Inc.
• Dimerix
• EpiEndo Pharmaceuticals
• Genentech
• GlaxoSmithkline
• GSNOR Therapeutics
• InMed Pharmaceuticals
• Ionis Pharmaceuticals
• KeyMed Biosciences
• Laboratoires SMB
• Mereo BioPharma
• Meridigen Biotech
• Nephron Pharmaceuticals
• Novartis
• Pulmatrix Inc.
• Pulmotect
• Quercegen Pharmaceuticals
• Regend Therapeutics
• Regeneron Pharmaceuticals/Sanofi
• Sulfateq BV
• Synairgen
• Tetherex Pharmaceuticals
• Verona Pharma
• Vertex Pharmaceuticals
• Yungjin Pharm. Co., Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kvobks

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900